ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
3.510
-0.080 (-2.23%)
Nov 17, 2026, 9:30 AM EST - Market open
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $37.71M in the quarter ending September 30, 2026, with 16.03% growth. This brings the company's total for the last twelve months to $122.14M, down -14.45% year-over-year. In the year 2025, ARS Pharmaceuticals had annual revenue of $84.28M, down -5.46%. That makes ARS Pharmaceuticals the 21,230th largest company in the world by revenue and 3,167th in the United States.
Revenue (ttm)
$122.14M
Revenue Growth
-14.45%
P/S Ratio
2.95
Revenue / Employee
$592,893
Employees
206
Market Cap
352.85M
Revenue by Geography
- United States 72.19M 85.7%
- Rest of World 12.09M 14.3%
Fiscal year ended Dec 31, 2025 See the full ARS Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.28M | -4.87M | -5.46% |
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 412.49M |
| Puma Biotechnology | 231.83M |
| Alector | 173.47M |
| Fennec Pharmaceuticals | 66.37M |
| Opus Genetics | 7.91M |
| SL Science Holding | 3.27M |
SPRY News
- 11 days ago - ARS Pharmaceuticals price target lowered to $20 from $30 at Cantor Fitzgerald - TheFly
- 11 days ago - ARS Pharmaceuticals downgraded to Outperform from Strong Buy at Raymond James - TheFly
- 11 days ago - ARS Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - ARS Pharmaceuticals Earnings release: Q3 2026 - Filings
- 11 days ago - ARS Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 11 days ago - ARS Pharmaceuticals reports Q3 EPS (36c), consensus (33c) - TheFly
- 19 days ago - ARS Pharma to Report Third Quarter 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 - GlobeNewsWire